Abstract:IntroductionChronic liver diseases (CLD) are common and may lead to fibrosis, cirrhosis, and hepatic malignancy.Detection and staging of liver fibrosis is crucial for management of patients with CLD.At present, liver biopsy is the standard method for staging fibrosis, but biopsies are poorly tolerated because they are invasive and associated with some discomfort and complications.In addition, limitations of biopsy include intra-and inter-observer variation and sampling error 1,2 .In recent years, a great interest and many studies have been dedicated to the development of noninvasive tests to substitute liver biopsy for fibrosis assessment and follow-up.Unfortunately, all of them have limitations and pitfalls.To discuss their advantages and deficiencies will be helpful in scientific research and clinical practice. Invasive measurements Liver biopsyLiver biopsy has been considered as the gold standard to confirm the clinical diagnosis, to assess the severity of necro-inflammation and fibrosis, to identify cofactors and comorbidities, and to monitor the efficacy of treatments since the first liver biopsy was performed by Paul Ehrlich in 1883 3 .The procedure is particularly useful for diagnosing the earlier stages of fibrosis and identifying patients at high risk of progressing fibrosis, but it has also a number of limitations.The patient acceptance is pretty low because biopsy is expensive, invasive and associated with some discomfort and complications.Pain appears in about one fourth of patients, other complications including bleeding, biliary peritonitis, pneumothorax and a mortality rate about 0.01% 4 .Sampling error of at least 24% is reported usually because of specimen fragmentation or inadequate length.Colloredo et al concluded that an optimum specimen should be at least 20 mm in length with 11 complete portal tracts 1 .Even with adequate-sized biopsies, the interpretation might be unreliable, because the distribution of necro-inflammation and fibrosis is not homogeneous, and liver biopsy samples only 1:50 000th of the mass of the liver.Several semi-quantitative scoring systems have been proposed to describe and quantify the necro-inflammation, steatosis and fibrosis in the liver, particularly for chronic viral hepatitis.These include the Knodell histological activity index (HAI) first proposed in 1981, then modified to the Scheuer system, the METAVIR system and the Ishak modified HAI 5 .However, all the scoring systems could only provide qualitative descriptors to stage fibrosis, www.intechopen.comLiver Biopsy 252 and the staging of certain histopathological changes differ in different systems (Table 1).This could cause considerable intra-and inter-observer variation and difficulty in comparison 2 .

A Clinical Review of Noninvasive Tests for Hepatic Fibrosis

Non-Invasive Assessment of Liver Fibrosis in Hepatitis B Patients

Noninvasive Alternatives for the Assessment of Liver Fibrosis

Assessment of Fibrosis in Chronic Liver Diseases

Noninvasive Assessment of Liver Fibrosis: Current and Future Clinical and Molecular Perspectives

Noninvasive assessment of liver fibrosis and portal hypertension

[Non-Invasive Test for Assessment of Liver Fibrosis in Chronic Hepatitis B]

Present situation on non-invasive assessment of liver fibrosis/cirrhosis

Advances of Noninvasive Methods in Diagnosis of Hepatic Fibrosis

Current Imaging Techniques for Noninvasive Staging of Hepatic Fibrosis

Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis

Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease

Non‐invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics

Non-invasive diagnosis and staging of non-alcoholic fatty liver disease

Diagnostic Estimation of Noninvasive Tests for Hepatic Fibrosis in Chronic Hepatitis B Patients Without a Gold Standard

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Advancements of non‐invasive imaging technologies for the diagnosis and staging of liver fibrosis: Present and future

Advances in Clinical Research of Hepatic Fibrosis

Non-invasive testing in metabolic dysfunction-associated steatotic liver disease

Noninvasive tools for the assessment of fibrosis in metabolic dysfunction-associated steatotic liver disease